Last reviewed · How we verify
NCT07164430
The Impact of the 2025 Infant and Maternal Respiratory Syncytial Virus (RSV) Prevention Program on RSV-related Hospitalisations in the Australian Capital Territory
trial in Respiratory Syncytial Virus (RSV) Infection in 2,792 participants. Completed in 31 January 2026.
31 January 2026
Quick facts
| Lead sponsor | Nicola Irwin |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,792 |
| Start date | 22 September 2025 |
| Primary completion | 31 January 2026 |
| Estimated completion | 31 January 2026 |
| Sites | 1 location across Australia |
Conditions studied
- Respiratory Syncytial Virus (RSV) Infection — all drugs for Respiratory Syncytial Virus (RSV) Infection →
- Respiratory Syncytial Virus Hospitalizations — all drugs for Respiratory Syncytial Virus Hospitalizations →
- Respiratory Syncytial Virus Immunization — all drugs for Respiratory Syncytial Virus Immunization →
Sponsor
Nicola Irwin
Who can join
Under 2, any sex, with Respiratory Syncytial Virus (RSV) Infection or Respiratory Syncytial Virus Hospitalizations. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to is to examine the impact of new RSV prevention medicines on the burden of RSV disease among young children. The main question it aims to answer is: What was the impact of the 2025 RSV prevention program on RSV-related hospitalisation in children under 2 years of age? Participants won't need to do anything additional for the study as only routinely collected health information will be used to answer the research question.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07164430
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Nicola Irwin trials
Trials by the same sponsor.
- NCT07177508 — First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australi · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07164430 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nicola Irwin
- Last refreshed: 5 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07164430.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing